GeoVax Labs, Inc. (GOVX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.4M) | (4.4M) | (5.3M) | (4.4M) |
| Net Income | (6.3M) | (4.4M) | (5.3M) | (4.4M) |
| Diluted EPS | $-7.75 | N/A | $-2.62 | $-0.97 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 82K | 0.00 | 4.0M | 2.5M |
| Operating Income | (14.0M) | (26.7M) | (25.1M) | (21.6M) |
| Net Income | (14.0M) | (26.0M) | (25.0M) | (21.5M) |
| Diluted EPS | $-311.25 | $-357.25 | $-120.46 | $-22.40 |